Supplementary information

Development of New Resolvin D1 Analogues: Acellular and Computational Approaches to Study Their Antioxidant Activities

Zahra Kariminezhad[1], Mahdi Rahimi[1], Julio Fernandes[1], René Maltais[2], Jean-Yves Sancéau[2], Donald Poirier[2,3], Hassan Fahmi[4], Mohamed Benderdour[1*]

[1] Orthopedic Research Laboratory, Hôpital du Sacré-Cœur de Montréal, Université de Montréal, Montréal, QC, Canada.
[2] Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.
[3] Organic Synthesis Service, Medicinal Chemistry Platform, CHU de Québec Research Center-Université Laval, Québec, QC, Canada.
[4] Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC, Canada
* Correspondance email: mohamed.benderdour@umontreal.ca; Tel.: (514 338- 2222 #3279)

RvD1 analogue 1:



Figure S1: ^{1}H NMR spectrum analogue 1



Figure S2: ^{13}C NMR spectrum analogue 1



Figure S3: LCMS chromatogram analogue 1



Figure S4: Mass spectrum analogue 1

RvD1 analogue 2:



Figure S5: ^{1}H NMR spectrum analogue 2



Figure S6: ^{13}C NMR spectrum analogue 2



Figure S7: LCMS chromatogram analogue 2



Figure S8: Mass spectrum analogue 2

Mulliken Charge Distribution:



Figure S9: Mulliken charge distribution for Trolox



Figure S10: Mulliken charge distribution for Ascorbic Acid



Figure S11: Mulliken charge distribution for ResolvinD1



Figure S12: Mulliken charge distribution for analogue 1



Figure S13: Mulliken charge distribution for analogue 2